News & Updates
Filter by Specialty:
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022
In patients with high-risk or unfavourable nonmetastatic prostate cancer (nmPC) receiving local definite therapy, the intensification of systemic therapy using chemotherapy or an androgen receptor signaling inhibitor (ARSI), in combination with androgen deprivation therapy (ADT), leads to better oncologic survival measures, reports a recent meta-analysis.
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022Intensive urate lowering of little benefit to patients with erosive gout
27 Apr 2022
A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.